Amphastar Pharma (AMPH) Tops Q4 EPS by 23c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.19, $0.23 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $76.9 million versus the consensus estimate of $64.48 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Worthington Industries (WOR) Misses Q4 EPS by 9c